for patients with multiple architectural distortion (AD) identified on digital breast tomosynthesis (DBT), biopsy of all areas may be warranted, given the variation of pathologic diagnoses across AD in individual patients

72-year-old woman recalled from screening mammography for architectural distortion in left breast. A. Craniocaudal and B. mediolateral oblique digital breast tomosynthesis images demonstrate two areas of AD in upper outer left breast (circles) that persisted on additional diagnostic tomosynthesis images (not shown). C. Transverse greyscale ultrasound image of upper outer breast shows irregular hypoechoic mass with associated AD at 12:30 (arrow), corresponding to posterior AD. No ultrasound correlate was identified for anterior AD. Ultrasound-guided biopsy of posterior AD revealed malignancy (invasive lobular carcinoma). Tomosynthesis-guided biopsy of anterior AD yielded benign pathology (stromal fibrosis). 


July 28, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), for patients with multiple architectural distortion (AD) identified on digital breast tomosynthesis (DBT), biopsy of all areas may be warranted, given the variation of pathologic diagnoses across AD in individual patients. 

“Multiple AD, compared with single AD, was significantly more likely to yield high-risk pathology, but there was no significant difference in yield of malignancy,” wrote corresponding author Lilian C. Wang, MD, of Northwestern Medicine. “In patients with multiple AD, multiple ipsilateral or contralateral AD commonly varied in pathologic classification: benign, high risk, or malignant.” 

Wang and colleagues’ retrospective study included 402 patients (mean age, 56 years) who underwent image-guided core needle biopsy of AD visualized on DBT between April 7, 2017, and April 16, 2019. Patients were grouped in the single or multiple AD cohort based on the presence of distinct AD areas noted in the clinical report, while the pathologic diagnosis for each AD was based on the most aggressive pathology identified on either biopsy or surgical excision (if performed). 

Ultimately, compared with single AD, multiple AD showed a higher frequency of high-risk pathology (53.0% vs. 32.5%, p=.002) but no significantly different frequency of malignancy on a per-lesion or per-patient basis (31.8% vs. 28.2%, p=.56). In 8/24 patients with ≥2 ipsilateral biopsied AD, the ipsilateral areas varied in terms of most aggressive pathology; in 5/10 patients with contralateral biopsied AD, the contralateral areas varied in most aggressive pathology.  

“To our knowledge,” the authors of this AJR article contended, “this is the first study to compare pathologic outcomes between patients with single and multiple AD visualized by DBT.” 

For more information: www.arrs.org 

Related Digital Breast Tomosynthesis Content: 

Today's Mammography Advancements 

Digital Breast Tomosynthesis Spot Compression Clarifies Ambiguous Findings 

AI DBT Impact on Mammography Post-breast Therapy 

ImageCare Centers Unveils PINK Better Mammo Service Featuring Profound AI 

Radiologist Fatigue, Experience Affect Breast Imaging Call Backs 

Fewer Breast Cancer Cases Between Screening Rounds with 3-D Mammography


Related Content

News | Artificial Intelligence

February 28, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered solutions that enable medical providers ...

Time February 28, 2024
arrow
News | Women's Health

February 27, 2024 — Hologic, Inc. continues to deliver on its commitment to advancing women’s health by unveiling new ...

Time February 27, 2024
arrow
News | Breast Imaging

February 23, 2024 — ScreenPoint Medical is showcasing its industry leading Transpara Breast AI at the 2024 European ...

Time February 23, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Breast Imaging

February 20, 2024 — Annual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the ...

Time February 20, 2024
arrow
News | FDA

February 15, 2024 — Merit Medical Systems, Inc., a global leader of healthcare technology, has received US Food and Drug ...

Time February 15, 2024
arrow
News | Breast Imaging

February 9, 2024 — An innovative breast imaging technique provides high sensitivity for detecting cancer while ...

Time February 09, 2024
arrow
News | Radiology Business

February 1, 2024 — Theragenics Corporation, a global leader in minimally invasive brachytherapy, interventional devices ...

Time February 01, 2024
arrow
News | FDA

January 30, 2024 — IceCure Medical Ltd. has announced the U.S. Food and Drug Administration (FDA) has responded ...

Time January 30, 2024
arrow
News | Breast Imaging

January 29, 2024 — Diagnoses of breast cancer have increased steadily in women under age 50 over the past two decades ...

Time January 29, 2024
arrow
Subscribe Now